Univariate analysis indicated that TGFBI was a prognostic predictor for ovarian cancer patients (HR = 1.16, 95% CI: 1.04–1.29, p < 0.01) (Fig. 1B and Figure S5A), and it was still proved to be an independent adverse factor in the multivariate analysis (HR = 1.35, 95% CI: 1.15–1.58, p < 0.01) (Fig. 1C and Figure S5B). Here, TGFBI is linked to ovarian carcinoma.